Table 2.

Instruments used to evalutate the efficacy of rivastigmine in treating Alzheimer’s disease

Instrument	Symptoms or domains assessed	Source of information	Range of scale and interpretation
Valutation of cognitive functions
Alzheimer’s disease assessment scale	Cognition (memory, language, orientation, praxis)	Patient	0–70 points 0 = no errors 70 = severe impairment
Mini Mental State Examination	Cognition (memory, language, orientation, attention, praxis),	Patients	0–30 points;30 = no errors, 0 = severe impairment
Valutation of global functions
Clinician interview based impression of change scale	Global assessment of behaviour, general psychopathology, cognition, and activities of daily living	Patient and caregiver	1–7 points 1,2,3 = minimal improvement 4 = no change 5,6,7 = marked deterioration
Progressive deterioration scale	Activities of daily living	Caregiver	29 items Scores range from 0 to 100